CRNX Crinetics Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Discovery, development, commercialization of novel small molecule GPCR-targeted therapies for endocrine diseases and endocrine-related tumors
• • New product: FDA approved PALSONIFY (paltusotine) in September 2025, first once-daily oral treatment for acromegaly adults inadequately managed by surgery
• • Strategic shift: Launching focused U.S. commercial organization for PALSONIFY; expanding globally with EMA marketing authorisation expected H1 2026 and Japan licensing deal
• • Key metric: Pipeline includes 10+ disclosed programs; active enrollment in Phase 3 trials for paltusotine in Cushing’s syndrome; positive Phase 2 data on atumelnant with Phase 3 initiated
• • Noteworthy fact: PALSONIFY’s approval marks first oral, nonpeptide SST2R agonist for acromegaly, representing a novel therapeutic class and offering improved patient convenience

Risk Factors

• • FDA approval risk: PALSONIFY regulatory compliance including U.S. FDA and EMA submissions with risk of delays or denial
• • Geopolitical risk: exposure to market disruptions from international conflicts including Russia-Ukraine and Middle East tensions
• • Supply chain risk: dependency on third-party manufacturers for clinical and commercial-scale production of PALSONIFY and other candidates
• • Competitive risk: potential market disruption if competitor therapies gain faster regulatory approval or wider physician acceptance
• • Financial risk: accumulated deficit $1.4B with reliance on $350M equity sales agreement for funding next 12 months

Management Discussion & Analysis

• • Revenue $7.7M in 2025 vs $1.0M in 2024, driven by $5.4M product sales from PALSONIFY launch
• • Operating margin -681.9% in 2025 vs -326.4% in 2024 (loss from ops $516.8M vs $338.9M on $7.7M vs $1.0M revenue)
• • Best segment: Collaboration revenue $2.3M up 119%, worst: operating expenses growth with SG&A up 92% to $191.3M
• • Cash, cash equivalents & investments $1.0B at end 2025 down 24%, raised $380M net in Jan 2026 equity offering, no dividends or buybacks
• • Outlook: Expects increasing product revenue but continued net losses; risks from R&D, commercialization costs, market acceptance, and global macro factors

What are the latest CRNX SEC filings in 2026?

Crinetics Pharmaceuticals, Inc. (CRNX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CRNX file its most recent 10-K annual report?

Crinetics Pharmaceuticals, Inc. (CRNX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CRNX 10-Q quarterly reports?

Crinetics Pharmaceuticals, Inc. (CRNX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every CRNX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CRNX filed recently?

Crinetics Pharmaceuticals, Inc. (CRNX)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CRNX insider trading activity (Form 4)?

SignalX aggregates every CRNX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CRNX file with the SEC?

Crinetics Pharmaceuticals, Inc. (CRNX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CRNX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Crinetics Pharmaceuticals, Inc. (CRNX).

What is CRNX's SEC CIK number?

Crinetics Pharmaceuticals, Inc. (CRNX)'s SEC CIK (Central Index Key) number is 1658247. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1658247 to look up all CRNX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CRNX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Crinetics Pharmaceuticals, Inc. (CRNX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.